Abstract 3462
Background
Tyrosine kinase inhibitors (TKI) and nivolumab (NIVO) are key components of systemic therapies in metastatic renal cell carcinoma (mRCC). We tested if TKI induction followed by an early switch to NIVO improved outcome in mRCC.
Methods
Key inclusion criteria were measurable advanced or metastatic ccRCC, ECOG PS 0-2, adequate organ function, and PR or SD after sunitinib (50 mg, 4-2 regime) or pazopanib (800 mg OD) for 10-12 weeks. 1:1 randomized to either continue TKI treatment or receive nivolumab 240 or 480 mg IV q2-4wks, until PD or intolerance. Imaging occurred q12wks and health-related quality of life (HR-QoL) was assessed monthly x3 and q12wks thereafter (FKSI-15). Primary and key secondary endpoints were survival rate at 2 years and ORR, respectively. The trial stopped prematurely for low accrual after 49 of 244 patients were randomized.
Results
25 and 24 pts. were randomized to receive NIVO or TKI continuation, respectively. Median age was 65 years (range: 35-79), 40 pts. (82%) were male and 2 pts. (4%) had an ECOG PS of 2. MSKCC risk categories: favorable, intermediate, poor were (n; %): 15 (31), 32 (65) and 2 (4). Pazopanib was used in 22 (45). Response to TKI induction was PR in 29 (59) and SD in 20 (41). In the ITT population, best overall response rate measured from start of induction therapy was not significantly different for NIVO vs. TKI (64 vs. 70%, P = 0.76). However, when measured from time of randomization, ORR for NIVO vs. TKI was 16 vs. 48% (P = 0.029). Adverse events (AE) for NIVO vs. TKI occurred in 96% vs. 100% (all grades) and 44% vs. 67% (grades 3-5), respectively. Serious AE (SAE) for NIVO vs. TKI continuation were reported in 10 (40) and 9 (38), respectively.Table:
959P Best overall response to nivolumab or TKI treatment (ITT population)
From start of TKI induction | From randomization | |||||
---|---|---|---|---|---|---|
Category | NIVO | TKI | Total | NIVO | TKI | Total |
n | 25 | 23 | 48 | 25 | 23 | 48 |
CR | -- | 1 (4%) | 1 (2%) | -- | 1 (4%) | 1 (2%) |
PR | 16 (64%) | 15 (65%) | 31 (65%) | 4 (16%) | 10 (43%) | 14 (29) |
SD | 9 (36%) | 7 (30%) | 16 (33%) | 6 (24%) | 7 (30%) | 13 (27%) |
PD | -- | -- | -- | 11 (44%) | 3 (13%) | 14 (29%) |
NE | -- | -- | -- | 4 (16%) | 2 (9%) | 6 (12%) |
Conclusions
TKI induction followed by early switch to NIVO did not improve ORR in patients responsive to TKI. These results do not support the notion that TKI pretreatment sensitizes for nivolumab efficacy. Major limitations of our trial are the premature closure and the limited sample size.
Clinical trial identification
2016-002170-13; NCT02959554.
Editorial acknowledgement
Legal entity responsible for the study
AIO-Studien-gGmbH, Berlin.
Funding
Bristol-Myers Squibb.
Disclosure
V. Grünwald: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Shareholder / Stockholder / Stock options: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Ipsen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Eisai; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Novartis; Research grant / Funding (self): Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Shareholder / Stockholder / Stock options: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Cerulean; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self), Shareholder / Stockholder / Stock options: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony: Art tempi; Advisory / Consultancy, Speaker Bureau / Expert testimony: Astellas; Advisory / Consultancy, Speaker Bureau / Expert testimony: COCS; Advisory / Consultancy, Speaker Bureau / Expert testimony: ClinSol; Advisory / Consultancy, Speaker Bureau / Expert testimony: EUSAPharm; Advisory / Consultancy, Speaker Bureau / Expert testimony: MedUpdate; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Serono; Advisory / Consultancy, Speaker Bureau / Expert testimony: MedKomAkademie; Advisory / Consultancy, Speaker Bureau / Expert testimony: NewConceptOncology; Advisory / Consultancy, Speaker Bureau / Expert testimony: Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Johnson & Johnson; Advisory / Consultancy, Speaker Bureau / Expert testimony: PharmaMar; Advisory / Consultancy, Speaker Bureau / Expert testimony: PeerVoice; Advisory / Consultancy, Speaker Bureau / Expert testimony: StreamedUp!; Advisory / Consultancy, Speaker Bureau / Expert testimony: ThinkWired!. All other authors have declared no conflicts of interest.
Resources from the same session
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract